OTC Markets OTCPK - Delayed Quote USD

Hemogenyx Pharmaceuticals Plc (HOPHF)

Compare
1.2400
0.0000
(0.00%)
At close: January 29 at 3:00:00 PM EST
Currency in GBP All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Cost of Revenue
1,682.2030
1,682.2030
2,196.8220
283.6470
267.0570
Gross Profit
-1,682.2030
-1,682.2030
-2,196.8220
-283.6470
-267.0570
Operating Expense
3,876.3450
3,876.3450
3,333.6650
2,546.9750
1,949.2400
Operating Income
-5,558.5480
-5,558.5480
-5,530.4870
-2,830.6220
-2,216.2970
Net Non Operating Interest Income Expense
-230.6470
-230.6470
10.5660
-2,577.4310
-29.8740
Pretax Income
-6,696.4930
-6,696.4930
-3,986.9820
-5,108.3100
-2,095.0230
Net Income Common Stockholders
-6,690.6780
-6,690.6780
-3,979.3140
-5,099.2280
-2,082.2200
Diluted NI Available to Com Stockholders
-6,690.6780
-6,690.6780
-3,979.3140
-5,099.2280
-2,082.2200
Basic EPS
-0.01
--
-0.01
-0.01
-0.01
Diluted EPS
-0.01
--
-0.01
-0.01
-0.01
Basic Average Shares
1,129,136.7270
--
979,749.3210
773,952.1660
414,833.0930
Diluted Average Shares
1,129,136.7270
--
979,749.3210
773,952.1660
414,833.0930
Total Operating Income as Reported
-6,465.8460
-6,465.8460
-3,997.5480
-2,702.7540
-2,150.3860
Total Expenses
5,558.5480
5,558.5480
5,530.4870
2,830.6220
2,216.2970
Net Income from Continuing & Discontinued Operation
-6,690.6780
-6,690.6780
-3,979.3140
-5,099.2280
-2,082.2200
Normalized Income
-6,690.6780
-6,690.6780
-3,979.3140
-5,271.1030
-2,082.2200
Interest Income
85.3440
85.3440
10.5990
17.9580
3.3650
Interest Expense
315.9910
315.9910
0.0330
2,595.3890
33.2390
Net Interest Income
-230.6470
-230.6470
10.5660
-2,577.4310
-29.8740
EBIT
-6,380.5020
-6,380.5020
-3,986.9490
-2,512.9210
-2,061.7840
EBITDA
-5,734.8210
-5,734.8210
-3,422.8770
-2,386.5810
-1,955.0310
Reconciled Cost of Revenue
1,682.2030
1,682.2030
2,196.8220
283.6470
267.0570
Reconciled Depreciation
645.6810
645.6810
195.2460
126.3400
106.7530
Net Income from Continuing Operation Net Minority Interest
-6,690.6780
-6,690.6780
-3,979.3140
-5,099.2280
-2,082.2200
Total Unusual Items Excluding Goodwill
--
--
--
171.8750
--
Total Unusual Items
--
--
--
171.8750
--
Normalized EBITDA
-5,734.8210
-5,734.8210
-3,422.8770
-2,558.4560
-1,955.0310
12/31/2020 - 1/12/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

INBX Inhibrx Biosciences, Inc.
13.55
+10.07%
 
MRNS Marinus Pharmaceuticals, Inc.
0.5406
-0.48%
 
APLS Apellis Pharmaceuticals, Inc.
30.39
+3.12%
 
ENTX Entera Bio Ltd.
2.3300
-2.10%
 
QNCX Quince Therapeutics, Inc.
1.6000
-2.44%
 
TARS Tarsus Pharmaceuticals, Inc.
51.74
-2.51%
 
NFX.L Nuformix plc
0.0750
-11.76%
 
IMUX Immunic, Inc.
1.0200
+3.03%
 
ANTX AN2 Therapeutics, Inc.
1.1700
-0.85%
 
JSPR Jasper Therapeutics, Inc.
6.70
+15.92%